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Abstract
The hypoxic tumor environment has been shown to be critical to cancer metastasis through the promotion of angiogenesis,
induction of epithelial-mesenchymal transition (EMT), and acquisition of invasive potential. However, the impact of hypoxia
on the expression profile of the proteolytic enzymes involved in invasiveness is relatively unknown. Membrane-type 4 matrix
metalloproteinase (MT4-MMP) is a glycosyl-phosphatidyl inositol–anchored protease that has been shown to be over-
expressed in human cancers. However, detailed mechanisms regarding the regulation and function of MT4-MMP expression
in tumor cells remain unknown. Here, we demonstrate that hypoxia or overexpression of hypoxia-inducible factor-1α (HIF-1α)
inducedMT4-MMP expression in human cancer cells. Activation of SLUG, a transcriptional factor regulating the EMT process
of human cancers, by HIF-1α was critical for the induction of MT4-MMP under hypoxia. SLUG regulated the transcription of
MT4-MMP through direct binding to the E-box located in its proximal promoter. Short-interferenceRNA–mediated knockdown
ofMT4-MMPattenuated in vitro invasiveness and in vivopulmonary colonization of tumor cellswithout affecting cellmigratory
ability. MT4-MMP promoted invasiveness and pulmonary colonization throughmodulation of the expression profile of MMPs
and angiogenic factors. Finally, coexpression of HIF-1α and MT4-MMP in human head and neck cancer was predictive of a
worse clinical outcome. These findings establish a novel signaling pathway for hypoxia-mediated metastasis and elucidate
the underlying regulatory mechanism and functional significance of MT4-MMP in cancer metastasis.
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Introduction
Intratumoral hypoxia caused by rapid proliferation of tumor cells is one
of the most important mechanisms promoting tumor aggressiveness,
metastasis, and resistance to therapy [1–5]. Tumor cell responses to
hypoxia are orchestrated in part through activation of the transcription
factor hypoxia-inducible factor-1 (HIF-1) [1–4]. HIF-1 is a hetero-
dimeric protein consisting of a constitutively expressed subunit, HIF-1β,
and a hypoxia-inducible subunit, HIF-1α. Stabilization of the HIF-1
transcriptional complex under hypoxic conditions promotes cancer
metastasis through three major mechanisms: promotion of angiogenesis,
induction of tumor cell epithelial-mesenchymal transition (EMT), and
activation/induction of proteolytic enzymes mediating tumor cell inva-
siveness [4]. Themost well-characterizedmechanism of hypoxia-induced
metastasis is the activation of vascular endothelial growth factor (VEGF)
by HIF-1 to promote angiogenesis [6,7]. Tumor hypoxia facilitates
lymphatic metastasis throughmodification of themigration and invasion
of lymphatic endothelial cells [5]. Increased HIF-1 activity can also in-
duce EMT, a critical mechanism for promotion of cancer cell metastasis,
through the activation of EMTregulators including SNAIL, SLUG (also
known as Snail2), TWIST, ZEB1, or SIP1 [4,8–13]. Finally, HIF-1 con-
tributes to the development of cancer cell invasiveness through activation
of proteolytic enzymes involved in cellular invasiveness (e.g., cathepsinD,
matrix metalloproteinase-2 [MMP-2], and urokinase plasminogen
activator receptor) [14,15]. However, in comparison with the well-
established mechanisms of hypoxia/HIF-1–induced angiogenesis and
EMT, the hypoxia/HIF-1 signaling pathways that regulate the activation
of proteolytic enzymes (i.e., the “degradome”) are relatively unknown.
MMPs are a family of zinc-binding endopeptidases that degrade
extracellular matrix components and modify the pericellular environ-
ment, thus playing a pivotal role in the regulation of cancer cell growth,
tumor-associated angiogenesis, and cancer metastasis [16–19]. The
MMP family of proteins includes both secreted and membrane-
anchored (i.e., membrane-typeMMP,MT-MMP) proteases, which have
distinct functions in mediating cancer cell invasiveness [20]. Membrane-
type 4 MMP (MT4-MMP, also known as MMP-17) is a member of
the glycosyl-phosphatidyl inositol–anchored membrane-type MMP
subgroup, which is structurally and functionally distant from other
MT-MMPs [20,21]. The importance of MT4-MMP in human cancers
has been suggested by previous studies, which reported that it is over-
expressed in human breast cancer tissues [22,23], and overexpression of
MT4-MMP accelerates the in vivo growth and promotes the metastasis
of breast cancer cells through alteration of the tumor vascular architec-
ture [23,24]. In comparison with the abundant information currently
available on the regulation and function of othermembrane-typeMMPs,
the mechanisms of MT4-MMP regulation and its function in cancer
remain to be established.
In this report, we explored one possible mechanism of MT4-MMP
regulation and its role in hypoxia-induced metastasis. SLUG, an EMT
regulator that is induced by hypoxia/HIF-1, is shown to directly regulate
the expression of MT4-MMP. We also demonstrate that MT4-MMP
plays a significant role in hypoxia-mediated metastasis and is also an
important prognostic indicator in patients with head and neck cancer.
Materials and Methods
Cell Culture and Oxygen Deprivation
The human hypopharyngeal squamous cell carcinoma cell line
FADU, tongue squamous cell carcinoma cell lines SAS and OECM-1,
and embryonic kidney 293T cell line were obtained from American
Type Culture Collection (Manassas, VA). FADU cells were cultured in
Roswell Park Memorial Institute (RPMI)-1640 medium with 10%
heat-inactivated fetal bovine serum (FBS), whereas 293T, SAS, and
OECM-1 cells were cultured in Dulbecco’s modified Eagle’s medium
with 10% FBS. Oxygen deprivation was carried out in a 37°C incubator
with 1% O2, 5% CO2, and 94% N2 for 18 hours.
Plasmids Construction and Short-interference
RNA Experiment
The pcDNA3-SNAIL, pFLAG-CMV, and pFLAG-TWIST plas-
mids were described [12]. The plasmids pHA-HIF-1α, pHA-HIF-
1α(ΔODD), and pHA-HIF-1α(LCLL) were gifts fromDr. L.E.Huang
(University of Utah) [25,26]. The plasmid pcDNA3–MT4-MMP
was generated by insertion of a 1821-bp fragment of the full-length
human MT4-MMP complementary DNA (cDNA) from the plasmid
pBluescriptR-(MT4-MMP) (Invitrogen Corporation, Carlsbad, CA)
into the BamHI/EcoRI sites of the pcDNA3.1 vector. The plasmid
pcDNA3-SLUG was generated by insertion of an 807-bp fragment
of the full-length human SLUG cDNA from the plasmid pCMV-
SPORT6-Snail2 (Genomic Center, National Yang-Ming University)
into the BamHI/EcoRI sites of the pcDNA3.1 vector.
For the short-interference RNA (siRNA) experiment, the plasmid
pSUPER-HIF-1α-si has been previously described [13]. The plasmids
pSUPER-SLUG-si and pSUPER–MT4-MMP-si were generated by
inserting an oligonucleotide containing siRNA target sequences specific
to SLUG or MT4-MMP into the pSUPER vector. A scrambled se-
quence with no significant homology to any mammalian gene sequence
was cloned into the pSUPER vector (pSUPER-scr-si) as a control for
the siRNA experiments as previously described [27]. The sequences of
the oligonucleotides used to generate the siRNA constructs are listed in
Table W1.
Protein Extraction and Western Blot Analysis
Protein extraction from cultured cells was performed as previ-
ously described [28]. The protein content was determined using the
Bradford method (Bio-Rad Laboratories, Hercules, CA). For Western
blot analysis, 50 μg of protein extract from each clone was loaded into
sodium dodecyl sulfate–polyacrylamide gels, proteins were separated
using electrophoresis, and the separated proteins were transferred to
nitrocellulose filters. The filters were probed with the appropriate pri-
mary antibody. An anti-glyceraldehyde 3-phosphate dehydrogenase
antibody was used as a loading control. Signals from bound antibodies
were developed using an ECL chemiluminescence kit (Amersham
Biosciences, London, UK). The characteristics of the antibodies used
in the Western blot analyses are listed in Table W2.
RNA Extraction, Reverse Transcription, and Quantitative
Real-time Polymerase Chain Reaction Analysis
Total RNA from cultivated cells were extracted using TRIzol reagent
(Invitrogen Life Technologies). cDNA synthesis was performed as pre-
viously described [28]. To evaluateHIF-1α andMT4-MMPmRNA ex-
pression, quantitative real-time polymerase chain reaction (PCR) was
performed using a PRISM7700 Sequence Detection System (Applied
Biosystems, Foster City, CA) with the preset PCR program. Glyceral-
dehyde 3-phosphate dehydrogenase was selected as an internal control
of each experiment. The primer sequences used in real-time PCR are
presented in Table W1.
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Cloning of the Human MT4-MMP and E-cadherin
Promoter Region, Generation of MT4-MMP– and
E-cadherin–driven Reporter Constructs, Transient
Transfection, and Luciferase Assays
The genomic regions flanking theMT4-MMP gene promoter region
(approximately −862 to +880 bp to ATG; Figure 4A) were generated
by PCR amplification of human genomic DNA and inserted into the
HindIII/BglII sites of the pXP2 vector to generate the MT4-Luc862 as
a parietal construct. The ATG translation initiation codon of MT4-
MMP was changed to CTG by site-directed mutagenesis to ensure
translation of luciferase open reading frame of the MT4Luc862 con-
struct. The MT4-Luc606, MT4-Luc433, MT4-Luc290, and MT4-
Luc57 constructs were generated from MT4-Luc862 parietal construct
for determining the putative regulatory region inMT4-MMP promoter.
The MT4-Luc862Mut construct was generated by changing the se-
quence from CACCTG (approximately −462 to −457 bp to ATG) to
AGAACT in MT4-Luc862 construct by site-directed mutagenesis (Fig-
ure 4A). The genomic regions flanking the E-cadherin gene promoter
region containing E-boxes (approximately −486 to −79 bp to ATG; Fig-
ure 3A) were generated by PCR amplification of human genomic DNA
and inserted into the HindIII/BglII sites of the pXP2 vector to generate
the Ecad-Luc486.
The reporter constructs were cotransfected into 293T cells with
pcDNA3-SNAIL, pcDNA3-SLUG, or pFLAG-TWIST and the inter-
nal control plasmid pcDNA3.1 or pFLAG-CMVunder either normoxic
or hypoxic conditions. A plasmid expressing the bacterial β-galactosidase
gene (pCMV-βgal) was also cotransfected in each experiment as an
internal control for transfection efficiency. Cells were harvested after
48 hours of transfection, and the luciferase activities were assayed as
described [13]. All values are expressed as the fold change in luciferase
activity after normalization using β-galactosidase activity.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed as
previously described [13]. Briefly, cell lysates were incubated with
no antibody, immunoglobulin G (IgG), or an antibody specific for
SLUG. The experimental PCR reactions generated a 196-bp product
from the regulatory region of the MT4-MMP gene containing an
E-box, whereas the control PCR reactions generated a 146-bp product
from a distal region without an E-box (Figure 4C , upper panel ). The
primers and antibodies used in the ChIP assays are listed in Tables W1
and W2.
Cell Migration and Invasiveness Assays
The Boyden chamber cell migration and invasion assays were per-
formed as previously described [29]. All experiments used 8-μm pore
size Boyden chambers. Briefly, cells (1 × 105) in medium contain-
ing 0.5% serum were seeded in the upper chamber, and 15% FBS
was added to medium in the lower chamber as a chemoattractant.
For invasion assays, the upper side of the filter was covered with
Matrigel (Collaborative Research, Inc, Boston, MA). After 12 hours
for migration assays or 24 hours for invasion assays, cells on the upper
side of the filter were removed, and cells that remained adherent to
the underside of membrane were fixed in 4% formaldehyde and
stained with Hoechst 33342 dye. Ten contiguous fields of each
sample were examined using a microscope and a 40× objective to
obtain a representation of the number of cells that had invaded across
the membrane.
In Vivo Tail Vein Metastasis Assay
Six-week-old female nonobese diabetic–severe combined immuno-
deficient (NOD-SCID) mice received injections of 1 × 106 cells of
different clonal cell lines (SAS-cDNA3, SAS-HIF1α(ΔODD)-si-scr,
SAS-HIF1α(ΔODD)-si-SLUG, SAS-HIF1α(ΔODD)-si–MT4-MMP,
SAS-SLUG-si-scr, SAS-SLUG-si–MT4-MMP, and SAS–MT4-MMP)
in 0.1 ml of PBS through the tail vein (n = 6 mice per group). Six weeks
after injection, mice underwent gross examination and necropsy to assess
the presence of metastases in the internal organs. Microscopic exami-
nation of metastases was performed on the cross sections of formalin-
fixed, paraffin-embedded lung tissues stained with hematoxylin and
eosin. The counting of metastatic lesions in the internal organ of each
mouse was evaluated by gross and microscopic examination. This
study was approved by the ethics committee of the Taipei Veterans
General Hospital.
Study Population, Sample Collection, Immunohistochemistry,
Validation of Antibodies, and Scoring
The records of sixty-eight patients with head and neck squamous
cell carcinoma (HNSCC) who underwent treatment at Taipei Veterans
General Hospital between January 2001 and December 2005 were
retrospectively analyzed. This study was approved by the institutional
review board of Taipei Veterans General Hospital. Patients’ clinical
characteristics are summarized in Table 1. Primary tumor samples and
corresponding non-cancerous matched tissue were obtained for anal-
ysis during surgery. Fixed tissue processing through deparaffiniza-
tion, rehydration, antigen retrieval, and immunohistochemistry (IHC)
was performed as previously described [28,29]. To validate the HIF-
1α and MT4-MMP antibodies used in IHC experiments, immuno-
cytochemistry (ICC) of HIF-1α was performed in 293T cells under
normoxia versus hypoxia, and ICC of MT4-MMP was performed
in 293T cells transfected with control vector versus pcDNA3–MT4-
MMP. Peptide blocking reagent without adding antibody was ap-
plied as the negative control of ICC experiments. The results showed
that anti–HIF-1α antibody could detect HIF-1α located in the nu-
cleus under hypoxia (Figure W4A), and the anti–MT4-MMP antibody
Table 1. Characteristics and Univariate Survival Analysis of 68 HNSCC Cases.
Variables Case No. Median OS (months) P
Age (years) .220
<50 28 —*
≥50 40 22.6
Sex .588
Male 65 22.6
Female 3 —*
T stage .026
1–2 30 —*
3–4 38 18.0
N stage <.001
0 50 —*
1-3 18 14.0
HIF-1α overexpression .006
Yes 28 14.0
No 40 —*
MT4-MMP overexpression .081
Yes 37 18
No 31 —*
HIF-1α/MT4-MMP coexpression .005
Yes 20 14.0
No 48 —*
OS indicates overall survival.
*Median survival was not reached.
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could detect cytoplasmic MT4-MMP in MT4-MMP–overexpressing
293T cells (Figure W4B). All antibodies used for IHC are listed in
Table W2.
HIF-1α and MT4-MMP IHC results were assessed independently
by two specialists. HIF-1α immunoreactivity was interpreted as previ-
ously described [13], with greater than 50% nuclear staining scored as a
positive result. MT4-MMP expression was scored with reference to
other membrane-cytoplasmic proteins [28,29], with only appreciable
staining distinctly marking the cytoplasm and/or nucleus, or dark stain-
ing completely obscuring the cytoplasm and/or nucleus in more than
25% of tumor cells considered as positive.
Statistical Analysis
An independent Student’s t-test was used to compare continuous vari-
ables between two groups, and a χ 2 test was applied for comparison of
dichotomous variables. A Kaplan-Meier estimate was used for survival
analysis, and a log-rank test was used to compare the cumulative survival
durations in the different patient groups. Unless otherwise specified in the
figure legends, the control groups for all the statistical analyses were the
first groups in the panels. Statistical significance was accepted when P <
.05 for all tests.
Results
Hypoxia or HIF-1α Overexpression Induces
MT4-MMP Expression
To identify the novel downstream targets of hypoxia in mediating
cancer metastasis, cDNA microarray analysis was performed in the
hypopharyngeal cancer cell line FADU under normoxic versus hypoxic
conditions. The result showed a significant increase in MT4-MMP
expression in FADU cells with hypoxia compared with cells in nor-
moxic conditions (data not shown). Because MT4-MMP has been re-
ported to be overexpressed in human cancers [22,23] and to promote
Figure 1. Hypoxia or constitutive expression of HIF-1α(ΔODD) upregulates MT4-MMP expression. (A) Upper: Fold change of mRNA
levels of HIF-1α and MT4-MMP by real-time RT-PCR analysis in FADU, SAS, and OECM-1 cells under normoxia versus hypoxia. Lower:
Western blot analysis of HIF-1α and MT4-MMP expression in FADU, SAS, and OECM-1 cells under normoxia versus hypoxia. (B) Upper:
relative mRNA expression levels of HIF-1α and MT4-MMP in FADU-HIF1α(ΔODD) versus FADU-cDNA3 (left) and SAS-HIF1α(ΔODD) ver-
sus SAS-cDNA3. Lower: HIF-1α and MT4-MMP protein levels in FADU-HIF1α(ΔODD) versus FADU-cDNA3 (left) and SAS-HIF1α(ΔODD)
versus SAS-cDNA3. (C) siRNA-mediated repression of endogenous HIF-1α abolishes the induction of MT4-MMP (mRNA and protein
levels) in SAS cells under hypoxia. Transfection of the vector containing a scrambled sequence against human transcriptome (si-scr)
was used as a control for siRNA experiments. The Western blot of MT4-MMP in all panels revealed two bands (upper indicates pro form;
lower, active form) indicated by black arrows. GAPDH was used as a loading control for Western blot analysis. N indicates normoxia; H ,
hypoxia. The asterisk (*) indicated statistical significance (P < .05) between experimental and control clones.
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metastasis [23,24], we speculated that MT4-MMP contributes to
hypoxia-induced metastasis. Because of the paucity of published data
on MT4-MMP in cancer cells, we firstly constructed the MT4-MMP
expression vector pcDNA3–MT4-MMP and validated the expression
efficiency of pcDNA3–MT4-MMP and the specificity of a commer-
cialized anti–MT4-MMP antibody (M3684; Sigma-Aldrich, Corp, St.
Louis, MO; see Table W2) by transient transfection of pcDNA3–MT4-
MMP or an empty vector into 293T cells. For MT4-MMP protein ex-
pression, Western blot revealed two bands at the expected molecular
weight (∼64 kDa), with the upper one being the pro form and the lower
one being the active form (Figure W1). This expression pattern was con-
sistent with the previous report [23].
To test whether MT4-MMP was indeed upregulated under hypoxia
in cancer cells, three HNSCC cell lines (hypopharyngeal cancer cell
line FADU and oral cancer cell lines SAS and OECM-1) were subject
to hypoxic stimulation. Quantitative real-time RT-PCR and Western
blot analysis of HIF-1α and MT4-MMP were performed to evaluate
differential HIF-1α/MT4-MMP expression under hypoxia versus nor-
moxia. Up-regulation of the mRNA and protein levels of HIF-1α and
MT4-MMP were demonstrated in all three cell lines under hypoxia
(Figure 1A). These results indicate that hypoxia induces MT4-MMP
expression in HNSCC cells.
Because the hypoxic response is mainly mediated by stabilization
and activation of the hypoxia inducible factor-1 (HIF-1) transcriptional
complex [30], we generated FADU and SAS clones, which constitu-
tively expressed a HIF-1α mutant harboring a deletion of the oxygen
degradation domain (ΔODD) that functions in a normoxic environ-
ment (FADU-HIF1α(ΔODD) and SAS-HIF1α(ΔODD)) [13,25].
When HIF-1α and MT4-MMP mRNA and protein levels were
examined in FADU-HIF1α(ΔODD) versus FADU-cDNA3 and
SAS-HIF1α(ΔODD) versus SAS-cDNA3, up-regulation of MT4-
MMP mRNA and protein levels was demonstrated in the FADU-
HIF1α(ΔODD) and SAS-HIF1α(ΔODD) clones (Figure 1B). To
confirm that HIF-1α was mostly responsible for the induction of
MT4-MMP by hypoxia, siRNA-mediated repression of HIF-1α was
performed in SAS cells exposed to hypoxia. The results showed that re-
pression of HIF-1α caused an almost complete repression of MT4-
MMP mRNA and protein expression to levels present under normoxic
conditions (Figure 1C). These findings suggested that a critical role for
HIF-1α in the induction of MT4-MMP by hypoxia. As further confir-
mation, immunofluorescent staining demonstrated the membranous-
cytoplasmic expression of MT4-MMP in SAS cells subjected to hypoxia
but not in SAS cells under normoxia or SAS cells expressing an inactive
HIF-1α mutant (HIF-1α-LCLL; see Figure W2A) [26]. Coexpression
Figure 2. Mapping of the major regulatory region in MT4-MMP promoter responsible for HIF-1α–induced transcriptional activation, and
hypoxia/HIF-1α upregulates the expression levels of SNAIL, TWIST, and SLUG. (A) Schematic representation of the promoter region of
MT4-MMP and reporter constructs containing different lengths of MT4-MMP promoter. The E-boxes and hypoxia response element
(HRE) are indicated. (B) Activation of MT4-Luc 862, MT4-Luc606, MT4-Luc433, MT4-Luc290, or MT4-Luc57 by hypoxia/HIF-1α over-
expression. The luciferase activity/β-galactosidase of 293T cells cotransfected with MT4-Luc862/pcDNA3.1 was applied as the baseline
control of other experiments (mean ± SD, n = 3; *P < .05 between experimental and control transfections). (C) Western blot analysis of
TWIST, SNAIL, and SLUG expression in FADU and SAS cells under normoxia (N) versus hypoxia (H). (D) Western blot analysis of TWIST,
SNAIL, and SLUG expression in FADU-HIF1α(ΔODD) versus FADU-cDNA3 (left) and SAS-HIF1α(ΔODD) versus SAS-cDNA3 (right).
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HIF-1α and MT-MMP was also shown in human HNSCC primary
tumor samples (Figure W2B). Collectively, these results indicate that
hypoxia or HIF-1α overexpression induces MT4-MMP expression in
HNSCC cells.
SLUG Is Responsible for Hypoxia or HIF-1α
Overexpression–Induced MT4-MMP Expression
To elucidate the mechanism by which HIF-1α increases MT4-
MMP expression, we generated the reporter construct MT4Luc862
containing proximal promoter region of MT4-MMP (Figure 2A).
Transient transfection assay showed that activation of MT4Luc862
to three-folds after hypoxic incubation, and cotransfection with wild-
type HIF-1α expression vector further increased the promoter activ-
ity to four-folds (Figure 2B). To map the major regulatory region of
MT4-MMP promoter responsible for hypoxia/HIF-1α overexpression,
different lengths of MT4-MMP promoter constructs were generated
(MT4-Luc606, MT4-Luc433, MT4-Luc290, and MT4-Luc57; Fig-
ure 2A) and transactivation assays were performed. The results deter-
mined the major region responsible for HIF-1α–induced MT4-MMP
transactivation: deletion of the E-box located in approximately −462 to
−457 to ATG abolished the promoter activity under hypoxia/HIF-1α
overexpression (Figure 2B). We therefore speculated that HIF-1α regu-
latesMT4-MMP expression indirectly through an E-box–binding tran-
scriptional factor. To find the E-box–binding transcriptional factor
responsible of HIF-1α–induced MT4-MMP transcriptional activa-
tion, we firstly screened the expression levels of different E-box bind-
ing proteins in FADU and SAS cells subjected to hypoxia. The result
demonstrated that SNAIL, TWIST, and SLUG were significantly
Figure 3. SLUG activates MT4-MMP expression and is critical for HIF-1α–mediated MT4-MMP induction. (A) Schematic representation of
the reporter constructs containing proximal promoter ofMT4-MMP (MT4-Luc862) or E-cadherin (Ecad-Luc486). (B) Left: Activation of MT4-
Luc862 by overexpression of TWIST, SNAIL, or SLUG. Right: Repression of Ecad-Luc486 by overexpression of TWIST, SNAIL, or SLUG. The
luciferase activity/β-galactosidase of 293T cells cotransfected with MT4-Luc862/pcDNA3.1/pFLAG-CMV (left) or Ecad-Luc486/pcDNA3.1/
pFLAG-CMV (right) was applied as the baseline control of experiments (mean ± SD, n = 3; *P < .05 between experimental and control
transfections). (C) Upper: Fold change ofmRNA levels ofMT4-MMP by real-time RT-PCR analysis in SAS cells overexpressing TWIST, SNAIL,
or SLUG. Lower: Western blot analysis of MT4-MMP expression in SAS cells overexpressing TWIST, SNAIL, or SLUG. (D) Upper: Relative
mRNA expression levels ofMT4-MMP in SAS-SLUG versus SAS-cDNA3. Lower:Western blot analysis of SLUG andMT4-MMP expression in
SAS-SLUG versus SAS-cDNA3. (E) siRNA-mediated repression of SLUG abolishes the HIF-1α–mediated induction of MT4-MMP expression
in SAS cells. Transfection of the vector containing a scrambled sequence against human transcriptome (si-scr) was used as a control for
siRNA experiments. The Western blot of MT4-MMP in (C), (D), and (E) revealed two bands (upper indicates pro form; lower, active form)
indicated by black arrows. GAPDH was used as a loading control for Western blot analysis. *Statistical significance (P < .05) between
experimental and control clones.
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upregulated under hypoxia in both cell lines (Figure 2C), and a consis-
tent result was shown in FADU or SAS cells overexpressing HIF-1α
(Figure 2D). To determine the major factor contributing to HIF-1α–
induced MT4-MMP up-regulation, transient transfection assay was
performed in 293T cells cotransfected with the MT4-Luc862 and
different expression vectors (pcDNA3-SNAIL, pcDNA3-SLUG, or
pFLAG-TWIST) or control vectors (pcDNA3.1 or pFLAG-CMV).
We also generated a reporter construct containing the proximal pro-
moter of E-cadherin (Ecad-Luc486) to confirm the suppressive effect
of SNAIL/TWIST/SLUG to E-cadherin promoter as a control of the
experiment (Figure 3A). The result demonstrated that SNAIL, SLUG,
and TWIST all harbored the inhibitory effect to E-cadherin promoter
(Figure 3B, right panel ); however, activation of MT4-MMP promoter
was only shown in SLUG-overexpressing cells (Figure 3B, left panel ).
This result indicates that SLUG is the major factor contributing to
MT4-MMP transactivation. To confirm this finding, overexpression
of SNAIL, SLUG, or TWIST was performed in SAS cells, and the
protein and mRNA levels of MT4-MMP were evaluated. Increased
MT4-MMP mRNA and protein expression was shown in SAS cells
overexpressing SLUG but not SNAIL or TWIST (Figure 3C ). To fur-
ther validate this result, we generated SAS clones with stable SLUG ex-
pression (SAS-SLUG clones; Figure 3D). An increase in MT4-MMP
mRNA and protein levels was demonstrated in the SAS-SLUG clones
compared with the control cells (Figure 3D). To demonstrate the critical
role of SLUG in HIF-1α–induced MT4-MMP expression, siRNA-
mediated repression of SLUG was performed in SAS-HIF1α(ΔODD)
cells. As predicted, MT4-MMP expression decreased after siRNA-
mediated repression of SLUG (Figure 3E ). Collectively, these results
suggest that SLUG is the major factor responsible for hypoxia/HIF-
1α–induced MT4-MMP expression.
Direct Regulation of MT4-MMP Expression by SLUG
To determine whether MT4-MMP is directly regulated by SLUG,
a putative SLUG binding site (the E-box sequence CACCTG; ap-
proximately −457 to −462 bp upstream from ATG) was identified
in the proximal promoter of the MT4-MMP gene (Figure 4A). Tran-
sient transfection assays showed a two- to three-fold increase in MT4-
MMP promoter activity after cotransfection with a SLUG expression
vector or with hypoxic incubation. Interestingly, hypoxia augmented
SLUG-induced MT4-MMP promoter activation by six-fold. Dele-
tion or site-directed mutagenesis of the SLUG binding site eliminated
promoter activation mediated by SLUG or hypoxia (Figure 4B). To
Figure 4. Direct regulation ofMT4-MMP by SLUG. (A) Schematic representation of the genomic organization of the promoter region ofMT4-
MMP and reporter constructs used in transient transfection assays. The constructs were wild-type (MT4-Luc862), E-Box–deleted (MT4-
Luc433), or E-box–mutated (MT4-Luc862Mut). (B) Transcriptional activation of MT4-Luc862, but not MT4-Luc433 and MT4-Luc862Mut by
SLUG, hypoxia or SLUG + hypoxia. The luciferase activity/β-galactosidase of 293T cells cotransfected with MT4-Luc862/pcDNA3.1 was ap-
plied as the baseline control of other experiments (mean ± SD, n = 3; *P < .05 between experimental and control transfections). (C) ChIP
analysis of SAS-SLUG, SAS-HIF1α(ΔODD) versus SAS-cDNA3. Chromatin was incubated without antibody, with an IgG, or with an anti-SLUG
antibody. The 196-bp fragment contains the Slug binding sequence, whereas the 146-bp fragment does not contain any Slug binding se-
quence. Schematic representation of the design of ChIP and control primers was shown in the upper panel. Input: 2% of total input lysate.
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confirm the in vivo binding of SLUG to the E-box in the MT4-MMP
promoter in HNSCC cells overexpressing HIF-1α or SLUG, ChIP
assays were performed in SAS-SLUG and SAS-HIF1α(ΔODD) versus
SAS-cDNA3 cell lines. The results showed that the PCR-amplified
fragments in theMT4-MMP promoter region containing the E-box site
(196 bp) could be retrieved from the immunoprecipitates by an anti-
SLUG antibody in both the SAS-SLUG and SAS-HIF1α(ΔODD)
samples but not in the SAS-cDNA3 sample (Figure 4C). These results
demonstrate that SLUG activates MT4-MMP transcription through
direct interaction with the E-box located in the proximal promoter of
the MT4-MMP gene.
MT4-MMP Contributes to HIF-1α– or SLUG-induced
In Vitro Invasiveness and Pulmonary Colonization in
Tail Vein Assay
To test whether MT4-MMP is critical for HIF-1α– or SLUG-
induced in vitro migration/invasion and in vivo settlement of tu-
mor cells in the lungs, in vitro migration/invasion assays and in vivo
tail vein assays were performed using the SAS-cDNA3 clone, SAS-
HIF1α(ΔODD) clones transfected with siRNA against SLUG or
MT4-MMP, and SAS-SLUG clones transfected with siRNA against
MT4-MMP. For the migration assays, overexpression of HIF-1α and
SLUG increased the migratory ability of SAS cells by approximately
three- to four-fold. Knockdown of SLUG in SAS-HIF1α(ΔODD)
clones partially suppressed migration. However, knockdown of
MT4-MMP did not influence cell migratory ability in either SAS-
HIF1α(ΔODD) or SAS-SLUG cell lines (Figure 5A).
A different scenario was observed in the invasion assays. Overexpres-
sion of HIF-1α and SLUG increased cell invasiveness by approximately
four- to five-fold, and knockdown of SLUG in SAS-HIF1α(ΔODD)
clones partially abolished cell invasiveness. Suppression of MT4-MMP
also inhibited the invasiveness in both SAS-HIF1α(ΔODD) and SAS-
SLUG clones (Figure 5B). A similar result was demonstrated in the
tail vein assay. Repression of SLUG in SAS-HIF1α(ΔODD) clones
Figure 5.MT4-MMP is critical in HIF-1α or SLUGmediated invasion and pulmonary colonization of tumor cells. (A) Fold change of migratory
ability of SAS-HIF1α(ΔODD) receiving siRNA against SLUG or MT4-MMP, and SAS-SLUG receiving siRNA-mediated MT4-MMP repres-
sion. (B) Fold change of invasiveness of SAS-HIF1α(ΔODD) receiving siRNA against SLUG or MT4-MMP, and SAS-SLUG receiving siRNA-
mediated MT4-MMP repression. (C) Representative pictures of metastatic pulmonary nodules (indicated by black arrows) in mice receiving
SAS-cDNA3, SAS-HIF1α(ΔODD)-si-scr, SAS-HIF1α(ΔODD)-si-SLUG, SAS-HIF1α(ΔODD)-si–MT4-MMP, SAS-SLUG-si-scr, and SAS-SLUG-si–
MT4-MMP injections. (D) Fold change of pulmonary tumor nodules of SAS-HIF1α(ΔODD) receiving siRNA against SLUG or MT4-MMP,
and SAS-SLUG receiving siRNA-mediated MT4-MMP repression. The migration/invasion/metastasis of SAS-cDNA3 clone was used as
the baseline control of all experiments, whereas transfection of the vector containing a scrambled sequence (si-scr) was used as a control
of siRNA experiments. *Statistical significance (P< .05) between the baseline control clone (SAS-cDNA3) and SAS-HIF1α(ΔODD)-si-scr/SAS-
SLUG-si-scr; **statistical significance (P < .05) between siRNA experimental clones (si-SLUG or si–MT4-MMP) and si-scr clones.
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decreased the capacity of tumor growth in the lung in these cells. In-
hibition of MT4-MMP expression also decreased pulmonary coloniza-
tion of both SAS-HIF1α(ΔODD) and SAS-SLUG clones (Figure 5, C
and D). These results showed that MT4-MMP participates in HIF-1α–
or SLUG-induced invasiveness and pulmonary colonization of cancer
cells without any substantial effects on cell migratory ability.
MT4-MMP Promotes In Vitro Invasiveness and In Vivo
Colonization and Growth of Tumor Cells in the Lungs,
Which Is Independent of EMT
To investigate whether overexpression of MT4-MMP alone could
induce metastasis, SAS clones that stably expressed MT4-MMP
(SAS–MT4-MMP) were generated (Figure 6A). When the ability of
MT4-MMP to induce cell migration and invasion was tested, the re-
sults showed that overexpression of MT4-MMP promoted SAS cell
invasiveness but not cell migration (Figure 6B). Because the induction
of EMT is critical for cancer metastasis, we evaluated changes in EMT
marker expression in SAS–MT4-MMP and SAS-cDNA3 cells. The
results showed that the expression levels of the epithelial marker E-
cadherin and mesenchymal marker N-cadherin were not different in
the experimental and control clones (Figure 6C ). However, MT4-
MMP significantly promoted the settlement and growth of tumor cells
in the lung in the tail vein metastasis assay (Figure 6D). These results
suggested that MT4-MMP may contribute to in vitro invasiveness
and in vivo colonization and growth of tumor cells in the lungs, which
is independent of EMT.
To test the influence of MT4-MMP on MMP and angiogenic factor
expression profiles, themajor cytokine families involved in cancer cell in-
vasiveness and metastasis, antibody arrays, including MMPs arrays and
angiogenic factors arrays, were screened using SAS–MT4-MMP and
SAS-cDNA3 cells. The results indicated that MT4-MMP indeed influ-
enced the expression profiles of MMPs and angiogenic factors, with the
decreased expression of MMP-8, tissue inhibitor of metalloproteinase-4
(TIMP-4; Figure W3, A and B), TIMP-2 (Figure W3, A–D), and in-
creased expression of basic fibroblastic growth factor (FigureW3,C and
D). Collectively, our results showed that overexpression of MT4-MMP
in cancer cells promoted invasiveness and settlement of tumor cells in
the lung through an EMT-independent mechanism, possibly involving
modulation of certain MMP family proteins and angiogenic factors.
Coexpression of HIF-1α and MT4-MMP Is a Prognostic
Marker of Human HNSCC
To investigate the clinical significance of MT4-MMP overexpres-
sion in HNSCC and its relationship to HIF-1α expression, IHC
analysis of HIF-1α and MT4-MMP expression was performed using
68 human HNSCC archived samples (Table 1). The specificity of
Figure 6. MT4-MMP contributes to invasiveness and pulmonary colonization of tumor cells through an EMT-independent mechanism.
(A) Western blot analysis MT4-MMP in SAS–MT4-MMP versus SAS-cDNA3. GAPDH was used as a loading control for Western blot
analysis. The Western blot of MT4-MMP revealed two bands (upper indicates pro form; lower, active form) indicated by black arrows.
(B) Fold change of migratory ability (left) and invasiveness (right) of SAS–MT4-MMP versus SAS-cDNA3. (C) Western blot analysis the
epithelial (E-cadherin) and mesenchymal (N-cadherin) markers in SAS–MT4-MMP versus SAS-cDNA3. (D) Left: Representative pictures
of metastatic pulmonary nodules (indicated by black arrows) in mice receiving SAS–MT4-MMP versus SAS-cDNA3 injections. Right:
Number of metastatic nodules counted in mice receiving SAS–MT4-MMP versus SAS-cDNA3 injections. *Statistical significance (P <
.05) between experimental clones and baseline control clone (SAS-cDNA3).
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the antibodies used in IHC experiments was validated by ICC assay
(Figure W4). The IHC results of two representative cases (case A,
coexpression of both markers; case B, negative for both markers)
are presented in Figure 7A. Overexpression of HIF-1α or MT4-
MMP detected by IHC was confirmed in 41.2% and 54.4% of cases,
respectively (Table 1). Overexpression of HIF-1α was also associated
with a worse prognosis of HNSCC cases (P = .006; Table 1), and
there was also a trend toward a worse outcome in patients overexpres-
sing MT4-MMP (P = .081; Table 1). Overexpression of HIF-1α was
closely associated with increased MT4-MMP expression (P = .018;
Table 2). To demonstrate the prognostic significance of the expres-
sion pattern of HIF-1α and/or MT4-MMP in HNSCCs, we divided
the patients into four protein expression groups, namely HIF-1α(−)/
MT4-MMP(−), HIF-1α(+)/MT4-MMP(−), HIF-1α(−)/MT4-
MMP(+), and HIF-1α(+)/MT4-MMP(+), and performed a Kaplan-
Meier survival analysis. When compared with other groups, patients
with the expression pattern of HIF-1α(+)/MT4-MMP(+) had a worse
Figure 7. Coexpression of HIF-1α and MT4-MMP in HNSCC cases indicates a worse survival, and a proposed model of hypoxia induced
metastasis through activation of MT4-MMP. (A) IHC staining of HIF-1α and MT4-MMP in two representative HNSCC cases with coexpres-
sion of HIF-1α/MT4-MMP (upper panel, cases A) and negative for both markers (lower panel, case B). N indicates normal epithelium; T ,
tumor tissues. The red arrows indicate the nucleus expression of HIF-1α, whereas the blue arrows indicate the membranocytoplasmic
expression of MT4-MMP. Scale bars, 200 μm. (B) Left: Comparison of the overall survival period of patients categorized by HIF-1α/
MT4-MMP IHC result. Right: Survival difference in HNSCC cases with or without HIF-1α/MT4-MMP coexpression. (C) A proposed model
of hypoxia induced metastasis through MT4-MMP.
Table 2. Correlation of the IHC Expression of HIF-1α and MT4-MMP in Primary Tumor Sam-
ples of 68 HNSCC Cases.
MT4-MMP P
Negative Positive
HIF-1α Negative 23 17 .018
Positive 8 20
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prognosis (Figure 7B, left panel ). We therefore divided cases into HIF-
1α/MT4-MMP coexpression versus non-coexpression. The coexpres-
sion cases had a significantly worse survival than did non-coexpression
cases (P = .005; Figure 7B, right panel ). These results support our ob-
servations from cell lines that activation of MT4-MMP by HIF-1α/
SLUG contributes to HNSCC metastasis.
Discussion
Increasing evidence indicates that tumor hypoxia has a critical role in
the promotion of metastasis through the induction of angiogenesis
and EMT. However, data addressing hypoxia/HIF-1α modulation
of tumor cell invasive proteolytic enzyme expression are relatively
scarce, with the exceptions of the activation of cathepsin D, MMP-
2, urokinase plasminogen activator receptor, plasminogen activator
inhibitor-1, and protease activator receptor-1 by HIF-1α [14,15,31,32].
Here, we provide evidence that activation of MT4-MMP by SLUG
contributes to hypoxia/HIF-1α–mediated cancer invasiveness and me-
tastasis. In support of this possibility, we have shown that hypoxia/
HIF-1α induces MT4-MMP expression through the activation of
SLUG, MT4-MMP is directly regulated by SLUG through binding
to its proximal promoter, MT4-MMP is critical for HIF-1α– or
SLUG-induced invasiveness/settlement and growth of tumor cells in
the lung, MT4-MMP promotes invasiveness and pulmonary coloniza-
tion of cancer cells through modulation of the invasive proteome and
angiogenesis in an EMT-independent mechanism, and tumor co-
expression of HIF-1α and MT4-MMP indicates a worse prognosis
in patients head and neck cancer. These results demonstrate a novel
signaling pathway in hypoxia-mediated metastasis and highlight the
critical role of MT4-MMP in hypoxic tumors.
As one of the major family of proteins involved in cancer me-
tastasis, correlations between MMPs and EMT have been well doc-
umented. Different MMPs have been shown to be regulated by
regulators of EMT. For example, MMP-2 and MMP-9 are regulated
by SNAIL [33,34]. In the present report, we demonstrate that
SLUG, a zinc-finger transcriptional factor that induces EMT through
suppression of E-cadherin expression [35,36], regulates MT4-MMP
expression, further supporting the correlation between EMT and
MMPs. Among the known MMPs, only MMP-3 has been shown
to induce EMT through Rac1b activity and increased concentrations
of reactive oxygen species [37]. In contrast to MMP-3, MT4-MMP
was unable to induce EMT in cancer cells. This result suggests that
MT4-MMP is located downstream of the hypoxia/EMT signal path-
way and that it mediates cancer metastasis.
Although MT4-MMP was shown to induce the in vivo metastasis
of breast cancer cells [23], the effect of MT4-MMP on the migratory
ability/invasiveness of cancer cells remains to be unequivocally dem-
onstrated. Chabottaux et al. [23] reported that overexpression of
MT4-MMP did not affect the in vitro invasiveness of the breast can-
cer cell line MDA-MB231 in a Boyden chamber assay. However,
Rizki et al. [38] suggested that MT4-MMP is functionally significant
in the acquisition of invasiveness. Using a similar assay, he demon-
strated that knockdown of MT4-MMP suppressed the invasiveness
of HMT-3522 breast tumor cells. In our study, we have shown that
overexpression of MT4-MMP had no effect on the migratory ability
of cancer cells but contributed significantly to both in vitro invasive-
ness and in vivo settlement of tumor cells in the lung in the tail vein
assay. These results were consistent with the outcome of siRNA ex-
periments, in which suppression of MT4-MMP in HNSCC cells
overexpressing HIF-1α or SLUG partially reduced in vitro cellular
invasiveness and in vivo pulmonary colonization of tumor cells with-
out affecting cell migratory ability. Because EMT is the major mech-
anism responsible for cancer cell migration [39], we speculated that
MT4-MMP may contribute to in vitro invasiveness and in vivo pul-
monary colonization of tumor cells through an EMT-independent
mechanism. Cytokine array experiments demonstrated MT4-MMP
modulates the expression profile of MMP family proteins and angio-
genic factors, including decreased expression of MMP-8, TIMP-2, and
TIMP-4 and increased expression of basic fibroblast growth factor. In
this regard, repression of MMP-8, which functions as a tumor suppres-
sor and is known as an “antitarget” for cancer therapy [40,41], by
MT4-MMP leads to the promotion of tumor metastasis and has a
negative impact on patient outcome. According to the above findings,
we suggest that MT4-MMP may contribute to invasiveness through
the modulation of the invasive proteome of tumor cells. Considering
the effect of MT4-MMP in the tail vein assay, we suggest that MT4-
MMP facilitates settlement and growth of tumor cells in the lung by a
so-far unknown mechanism because the tail vein injection of tumor
cells into NOD-SCID mice cannot totally reflect the metastatic ability
of cancer cells. The underlying cause of increased pulmonary coloni-
zation in MT4-MMP overexpressing cancer cells may attribute to the
modulation of invasive proteome and angiogenic ability.
In conclusion, this report establishes a new, stepwise signaling
pathway from hypoxia/HIF-1 to SLUG to MT4-MMP and demon-
strates the critical role of MT4-MMP in hypoxia-induced cancer cell
metastasis. A new proposed model for this pathway is outlined in
Figure 7C . These results should significantly impact future cancer
therapeutic interventions and avenues for the prevention of hypoxic
tumor metastasis.
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Supplemental Materials and Methods
Immunofluorescence
For immunofluorescence staining of cultivated cells, cells on glass
coverslips were fixed and permeated, then incubated with primary
antibodies. Fluorescein isothiocyanate– or rhodamine-conjugated
secondary antibodies were used to visualize the location of HIF-1α/
MT4-MMP. Cell nuclei were counterstained with Hoechst 33342
(Sigma-Aldrich Corp), and fluorescence images were captured using
a Leica DMRE epifluorescence microscope (LeiCa TCS SP2, Wetzlar,
Germany). For immunofluorescence staining of tumor samples, sam-
ples were processed with deparaffinization, rehydration, and antigen
retrieval. The subsequent procedures were identical to cellular immuno-
fluorescence. All the antibodies used in immunofluorescence are listed
in Table W2.
Cytokine Antibody Arrays
RayBio Human Matrix Metalloproteinase Antibody Array 1 (no.
AAH-MMP-1) and RayBio Human Angiogenesis Antibody Array 1
(no. AAH-ANG-1) (RayBiotech, Inc, Norcross, GA) were performed
according to the user manual. Briefly, array membranes were incubated
for 30 minutes in blocking buffer and then incubated for 2 hours with
the conditioned medium collected from SAS-cDNA3 versus SAS–
MT4-MMP clones. The membranes were washed, and a diluted cock-
tail of biotinylated antibodies was added for 90 minutes. Membranes
were then washed again, and the sandwiched antigens were detected by
incubation for 2 hours with a peroxidase-labeled streptavidin solution
diluted to 1:1000. Proteins were detected finally by enhanced chemi-
luminescence, and signals were captured. Array images were quantified
with ImageQuant TL software version 5.2 (Amersham Biosciences,
Inc., Piscataway, NJ). For each spot, the net density gray level was de-
termined by subtracting the background gray level from the total raw
density gray levels. Data after background subtraction were normalized
according to positive control densities.
Table W1. Sequence of the Oligonucleotides for siRNA Construct-Making, Real-time PCR, and ChIP Assays.
Assays Sequence (5′ → 3′) Amplicon
SiRNA HIF-1α-si GATCCCCGAATTCTCAACCACAGTGCTTCAAGAGAG-
CACTGTGGTTGAGAATTCTTTTTA
MT4-MMP-si GATCCCCCCCACTTTGACGATGACGATTCAAGAGATCGT-
CATCGTCAAAGTGGGTTTTTA
SLUG-si GATCCCCGATGCATATTCGGACCCACTTCAAGA-
GAGTGGGTCCGAATATGCATCTTTTTA
scramble-si GATCCCCGTGTCTGTAGGAGTCATCCTTCAAGAGAGGAT-
GACTCCTACAGACACTTTTTA
Real-time PCR HIF-1α F AAACTTCTGGATGCTGGTGATTTG 220
R TTTCCTCATGGTCACATGGATGA
MT4-MMP F CTGGGAGTGGAGTGGCTAAGCA 168
R TTTCATCAGGGCCAGGGTGG
GAPDH F AAGGTCGGAGTCAACGGATTTG 149
R CCATGGGTGGAATCATATTGGAA
ChIP MT4-MMP ChIP primer F ACACCCGCCCTCGCCCTC 196
R CTGACCCTGACTCCCCTCTCCG
MT4-MMP control primer F TGTTGCTGTGAGACTTGGTCCAG 146
R ATCAGGACAACCTGGTTTCCAGA
Table W2. List of Proteins Tested by Antibodies and Characteristics of the Corresponding Anti-
bodies Used.
Protein Assay Antibody Origin Dilution Incubation Period
HIF-1α WB No. 610959, BD Biosciences Mouse 1:1000 Overnight, 4°C
HIF-1α IHC No. 610959, BD Biosciences Mouse 1:100 Overnight, 4°C
HIF-1α IF No. 610959, BD Biosciences Mouse 1:100 Overnight, 4°C
MT4-MMP WB M3684, Sigma-Aldrich Corp Rabbit 1:1000 Overnight, 4°C
MT4-MMP IHC M3684, Sigma-Aldrich Corp Rabbit 1:200 Overnight, 4°C
MT4-MMP IF M3684, Sigma-Aldrich Corp Rabbit 1:50 Overnight, 4°C
SLUG WB No. 9589, Cell Signaling
Technology, Inc
Mouse 1:1000 Overnight, 4°C
SLUG ChIP No. 9589, Cell Signaling
Technology, Inc
Mouse 1:100 Overnight, 4°C
E-cadherin WB No. 4065, Cell Signaling
Technology, Inc
Rabbit 1:1000 Overnight, 4°C
N-cadherin WB No. 610921, BD Biosciences Mouse 1:1000 Overnight, 4°C
GAPDH WB No. LF-PA0018, Abfrontier
Co, Ltd
Rabbit 1:8000 Overnight, 4°C
IF indicates immunofluorescence; WB, Western blot.
Figure W1. Validation of the efficacy of the constructed MT4-MMP
expression vector (pcDNA3–MT4-MMP), specificity of an anti–MT4-
MMP antibody used in experiments, and the expression pattern of
MT4-MMP protein in Western blot. Western blot analysis of MT4-
MMP in 293T cells transfected with pcDNA3–MT4-MMP versus
pcDNA3.1 empty vector. The Western blot of MT4-MMP revealed
two bands (upper indicates pro form; lower, active form) indicated by
black arrows.GAPDHwasusedas a loadingcontrol for the experiment.
Figure W2. Nuclear expression of HIF-1α promotes membranocytoplasmic expression of MT4-MMP in HNSCC cell lines and samples.
(A) Immunofluorescence staining of HIF-1α/MT4-MMP in SAS cells under normoxia (upper panels), hypoxia (middle panels), or express-
ing inactive HIF-1αmutant (HIF1α(LCLL)) (lower panels). The green signal represented the staining of MT4-MMP, whereas the red signal
represented the staining of HIF-1α. The blue signal represented nuclear DNA staining by Hoechst 33342. (B) Immunofluorescence stain-
ing of HIF-1α/MT4-MMP in a representative HNSCC case. The green signal represented the staining of MT4-MMP, whereas the red sig-
nal represented the staining of HIF-1α. The blue signal represented nuclear DNA staining by Hoechst 33342. Scale bars: A, 20 μm; and
B, 200 μm.
Figure W3. Expression profiles of MMPs and angiogenic proteins in SAS–MT4-MMP versus control. (A) Representative picture (upper)
with corresponding labeling (lower) of a MMPs array in SAS–MT4-MMP versus SAS-cDNA3. The proteins with significant change were
circled with broken line. (B) Quantification of protein expression changes in the MMPs array of SAS–MT4-MMP versus SAS-cDNA3. (C)
Representative picture (upper) with corresponding labeling (lower) of an angiogenic factors array in SAS–MT4-MMP versus SAS-cDNA3.
The proteins with significant change were circled with broken line. (D) Quantification of protein expression changes in the angiogenic
factors array of SAS–MT4-MMP versus SAS-cDNA3.
Figure W4. Validation of anti–HIF-1α and anti–MT4-MMP antibodies used in IHC experiments. (A) ICC of HIF-1α in 293T cells under
normoxia versus hypoxia. No antibody (Ab) was applied as the negative control of ICC experiment. (B) ICC of MT4-MMP in 293T cells
transfected with control vector versus pcDNA3–MT4-MMP. No Ab was applied as the negative control of ICC experiment. Scale bars,
100 μm.
